Literature DB >> 16865518

Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case.

Michiya Kobayashi1, Ken Okamoto, Hajime Nakatani, Takehiro Okabayashi, Tsutomu Namikawa, Kengo Ichikawa, Hiroyuki Kitagawa, Keijiro Araki.   

Abstract

A 49-year-old man underwent partial resection of the jejunum for an abdominal tumor, which was histologically confirmed to be a gastrointestinal stromal tumor (GIST). Immunohistochemistry revealed that the tumor cells were positive for c-kit, p52, and MIB-1. He underwent resection of a total of 83 recurrent tumors over the next 36 months. A computed tomography (CT) scan done a few months later showed multiple tumor recurrences. The patient was started on imatinib mesylate 400 mg/day, and 3 months later, a CT image showed an increase in tumor size but a decrease in tumor density. Subsequent CT scans showed a marked decrease in tumor size 3 months later and no evidence of tumor recurrence 9 and 12 months after the commencement of imatinib treatment. The patient remains in complete remission 31 months after the start of treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865518     DOI: 10.1007/s00595-006-3224-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  24 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

4.  Gastrointestinal stromal tumor workshop.

Authors:  J Berman; T J O'Leary
Journal:  Hum Pathol       Date:  2001-06       Impact factor: 3.466

5.  Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

Authors:  M Zalupski; B Metch; S Balcerzak; W S Fletcher; R Chapman; J D Bonnet; G R Weiss; J Ryan; R S Benjamin; L H Baker
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

6.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

Authors:  D A Tuveson; N A Willis; T Jacks; J D Griffin; S Singer; C D Fletcher; J A Fletcher; G D Demetri
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

7.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor.

Authors:  Akira Sawaki; Kazuhiko Ohashi; Kenji Yamao; Ken-Ichi Inada; Yasuhiro Shimizu; Akira Matsuura; Tuneya Nakamura; Takashi Suzuki; Kazuo Hara; Kenji Okubo; Ryuzo Ohno
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

Review 9.  Biology of gastrointestinal stromal tumors.

Authors:  Christopher L Corless; Jonathan A Fletcher; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

View more
  1 in total

1.  18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models.

Authors:  Anuradha Soundararajan; Jinu Abraham; Laura D Nelon; Suresh I Prajapati; Lee Ann Zarzabal; Joel E Michalek; Stanton F McHardy; Douglas S Hawkins; Suman Malempati; Charles Keller
Journal:  Pediatr Blood Cancer       Date:  2012-01-11       Impact factor: 3.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.